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Abstract
Background: Transparency in reporting of conflict of interest is an increasingly important aspect of publication in medical
journals. Publication of large industry-supported trials may generate many citations and journal income through reprint
sales and thereby be a source of conflicts of interest for journals. We investigated industry-supported trials’ influence on
journal impact factors and revenue.
Methods and Findings: We sampled six major medical journals (Annals of Internal Medicine, Archives of Internal Medicine,
BMJ, JAMA, The Lancet, and New England Journal of Medicine [NEJM]). For each journal, we identified randomised trials
published in 1996–1997 and 2005–2006 using PubMed, and categorized the type of financial support. Using Web of Science,
we investigated citations of industry-supported trials and the influence on journal impact factors over a ten-year period. We
contacted journal editors and retrieved tax information on income from industry sources. The proportion of trials with sole
industry support varied between journals, from 7% in BMJ to 32% in NEJM in 2005–2006. Industry-supported trials were
more frequently cited than trials with other types of support, and omitting them from the impact factor calculation
decreased journal impact factors. The decrease varied considerably between journals, with 1% for BMJ to 15% for NEJM in
2007. For the two journals disclosing data, income from the sales of reprints contributed to 3% and 41% of the total income
for BMJ and The Lancet in 2005–2006.
Conclusions: Publication of industry-supported trials was associated with an increase in journal impact factors. Sales of
reprints may provide a substantial income. We suggest that journals disclose financial information in the same way that they
require them from their authors, so that readers can assess the potential effect of different types of papers on journals’
revenue and impact.
Please see later in the article for the Editors’ Summary.
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Many medical journals require that authors and peer reviewers
declare whether they have any conflicts of interest. Such
knowledge can be important for readers when assessing the paper
and for editors when assessing the peer review comments.
Editors can also have conflicts of interest, and the International
Committee of Medical Journal Editors states that: ‘‘Editors who
make final decisions about manuscripts must have no personal,
professional, or financial involvement in any of the issues they
might judge’’ [1]. Furthermore, editors are advised to ‘‘publish
regular disclosure statements about potential conflicts of interest
related to the commitments of journal staff’’ [1].
Journals may have other conflicts of interest than those of their
editors, and the most important of these is likely related to the
publication of industry-supported clinical trials. It is important for
the industry to publish reports of large trials in prestigious journals,
as such reports are essential for clinical decision making and for
the sales of drugs and devices [2,3]. However, journals not only
stand to gain financially through the sales of reprints, but also
publication of such trials may increase their impact factors, as a
large number of reprints distributed to key clinicians by drug
companies will likely increase citation rates. For example, The New
England Journal of Medicine (NEJM) sold about one million reprints
to Merck of its paper on the VIGOR trial of rofecoxib [4].
One survey found that the policies on conflicts of interest for
individual editors vary between journals [5], but we have not been
able to identify any empirical studies on conflicts of interest at
medical journals.
We investigated the influence of industry-supported randomised
trials on impact factors for major general medical journals and
describe the relative income from the sales of advertisements,
reprints, and industry-supported supplements.
Methods
The impact factor for a given year is calculated as the number of
citations in that year to papers published in the two previous years,
divided by the number of citable papers published in the two
previous years [6]. We focused on two time periods, citations in
1998 for randomised clinical trials (RCTs) published in 1996–1997
and citations in 2007 for RCTs published in 2005–2006, and
retrieved citation data using Web of Science on the ISI Web of
Knowledge [7].
On the basis of a pilot (see Text S1) that included journals
categorised as ‘‘Medicine, General & Internal’’ in Journal Citation
Reports on the ISI Web of Knowledge [8] with an impact factor of
five or higher in 2007, which identified ten journals, we decided to
include six major general medical journals: Annals of Internal
Medicine (Annals), Archives of Internal Medicine (Archives), BMJ, JAMA,
The Lancet (Lancet), and NEJM. Trials published in these journals in
the two time periods were identified using PubMed’s limits
function for journal name, publication date, and the publication
type Randomized Controlled Trial. Papers that were not full
reports of trials (e.g., letters, commentaries, and editorials) were
excluded. We extracted information on journal name, title,
publication year, and type of support into a standardised data
sheet. Data extraction and retrieval of citation data were done
independently by two authors (AL, MB), and discrepancies were
resolved by discussion.
Type of Support
We categorised the support as industry support, mixed support,
nonindustry support, or no statement about support. We defined
industry support as any financial support, whether direct or
indirect (e.g., grants, industry-employed authors, assistance with
data analysis or writing of the manuscript, or provision of study
medication or devices by a company that produces drugs or
medical devices). We did not regard a study as industry-supported
if the only interaction with industry was author conflicts of interest
(e.g., honorariums, consultancies, and membership of advisory
boards). We defined nonindustry support as any other type of
financial support. Mixed support was any support provided by
both industry and nonindustry sources, and no statement about
support if nothing was stated in the paper.
Citations of Individual Trials and of All Papers
We identified the number of citations for each identified RCT
using the function ‘‘refine by publication year’’ in Web of Science.
This was done in July and August 2009, blinded to the study
support of the individual trials. We also identified the total number
of citations (the numerator of the impact factor) using the function
‘‘create citation report’’ in Web of Science.
In our pilot study we compared the number of citations using
Web of Science with the numbers used for the ‘‘official’’ impact
factor calculation published in Journal Citation Reports and we
discovered that the numbers of citations in Web of Science were
lower (see Text S1). Correspondence with the publisher, Thomson
Reuters, revealed that the citations from Web of Science and
Journal Citation Reports are not similar, as they are not based on
the same data. For example, studies that are referenced incorrectly
are only included in Journal Citation Reports. But determinants
leading to a citation not being identified in Web of Science can be
assumed to be random and unrelated to study type and support.
As our aim was to look at the relative contribution of industry-
supported trials to the impact factor, we proceeded with our
planned analyses, calculating an approximate impact factor.
Denominator of Impact Factor
We identified the number of citable papers (denominator of
impact factor) published in 1996–1997 and 2005–2006 for each
journal using the most recent Journal Citation Report with
available data.
Financial Income and Reprint Sales
In November 2009, we contacted the Editor-in-Chief of each of
the six journals by e-mail and requested data on income from sales
of advertisements, reprints, and industry-supported supplements (if
any), as percentage of total income for the journal, and the total
number of reprints sold, in both cases in 2005 and 2006.
BMJ and Lancet provided the data, but the editors of Archives,
JAMA, and NEJM did not provide the data, as it was their policy
not to disclose financial information. Annals forwarded our request
to the publisher who declined for similar reasons.
For these four American journals, we therefore needed to use
proxy data. We obtained the publicly available tax information
stated in the Internal Revenue Service Form 990 (tax form
required for nonprofit organizations) for 2005 and 2006 for the
journal owners: American College of Physicians (ACP) for Annals,
American Medical Association (AMA) for Archives and JAMA, and
Massachusetts Medical Society (MMS) for NEJM. These data
report on the total income from all types of publishing by the
societies, and as all societies publish more than one journal, we
could not obtain data for individual journals. ACP publishes three
other journals in the ACP series and books; AMA publishes eight
other journals in the Archives series, an additional journal, and
Web-based material; and MMS publishes various article summa-
ries in their Journal Watch series. We contacted the journal
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from industry sources based on tax information. ACP confirmed
our calculations, but AMA and MMS did not reply, despite
numerous e-mails.
Statistical Analyses
For each journal, we compared the distribution of support of
trials published in the two time periods with the Mann-Whitney
U-test (two-sided). In an a priori stated sensitivity analysis, we
recategorised trials with no statement about support as nonindus-
try supported.
On the basis of our own citation data derived from the
individual trials, we compared the number of citations of trials
with industry support with those with mixed support and those
with nonindustry support using the Jonckheere-Terpstra test for
trend (two-sided). As the category ‘‘not stated’’ is a mix of the three
other categories we did not include this in our test. To test the
robustness of our findings, we did various a priori stated sensitivity
analyses (e.g., change in criteria used for industry support) (see
Text S1).
We calculated what an approximate impact factor would have
been, for each of the six journals for each time period, if no trials
with industry support had been published; this calculation was
done by excluding trials with industry support from the numerator
and the denominator. We did the same calculations using a
broader category of industry-supported trials that also included
those with mixed support. We estimated the percentage reduction
in impact factor that resulted from exclusion of these trials.
We had intended to study the association between mean
number of citations to trials and percent income from reprints, but
this was not possible as only the two European journals provided
the data we requested.
Results
We identified 1,429 papers indexed as Randomized Controlled
Trials in PubMed (see Text S1) and excluded 61 letters, three
editorials, five commentaries, and seven papers that were e-
published ahead of print, which yielded a total sample size of 1,353
included RCTs (651 from 1996–1997 and 702 from 2005–2006).
For Annals and Lancet, the number of trials decreased over time,
whereas it increased for the other journals (see Table 1). The total
number of citable papers decreased for all journals, except Archives.
Hence, there was an increase in the proportion of trials out of all
citable papers for all journals over time, with BMJ and JAMA
having around a 3-fold increase and NEJM having the highest
proportion of trials in both periods.
Type of Support
The type of support varied markedly across journals (see
Table 1). In 2005–2006, NEJM had the highest proportion of trials
with industry support (32%) and BMJ the lowest (7%). The
proportion of trials that were industry-supported declined from
1996 to 2005 for all journals except NEJM, where it was constant.
The decline was statistically significant for Annals and Archives; for
BMJ, the proportion declined by nearly half (from 13% to 7%),
but this was not statistically significant.
Citations of Individual Trials
For trials published in 1996–1997, there was a significant
relation between the number of citations and the degree of
industry support (three categories on a ranking scale) for Lancet
(p=0.003) and NEJM (p=0.003), whereas for trials published in
2005–2006, the relation was statistically significant for all journals
(see Table 2). Industry-supported trials published in Annals,
Archives, and Lancet in 2005–2006 were cited more than twice as
often as nonindustry trials, and one and a half times more in BMJ,
JAMA, and NEJM.
Our a priori defined sensitivity analyses found minor discrep-
ancies, but overall the results were robust (see Text S1).
Approximate Impact Factor
The approximate impact factor we calculated decreased for all
journals when industry-supported trials were excluded from the
calculation, and the decrease was larger when trials with mixed
support were also excluded (see Table 2). The decrease was highest
for NEJM, followed by Lancet, whereas the impact factor of BMJ
was barely affected. The decrease in approximate impact factor
varied minimally between the two time periods for all journals,
except for Lancet, where the decrease was 11% in 1996–1997 and
6% in 2005–2006 when trials with industry and mixed support
were excluded.
Financial Income and Reprint Sales
In 2005–2006, 16% of the income for BMJ was from display
advertisements, 3% from reprints, and 0% from supplements, and
967,930 reprints were sold (see Table 3). For Lancet, the
percentages were 1% from display advertisements, 41% from
Table 1. Description of support of randomised controlled trials published in major general medical journals.
Support Annals Archives BMJ JAMA Lancet NEJM
1996–
1997
2005–
2006
1996–
1997
2005–
2006
1996–
1997
2005–
2006
1996–
1997
2005–
2006
1996–
1997
2005–
2006
1996–
1997
2005–
2006
n trials (%) 71 (16) 58 (17) 67 (13) 80 (13) 91 (6) 116 (16) 76 (7) 113 (19) 186 (12) 129 (20) 160 (20) 206 (34)
Total n citable papers 458 339 519 593 1624 745 1120 590 1515 661 785 611
Support of trials
Industry support (%) 19 (27) 11 (19) 22 (33) 12 (15) 12 (13) 8 (7) 23 (30) 29 (26) 47 (25) 28 (22) 51 (32) 66 (32)
Mixed support (%) 27 (38) 20 (34) 14 (21) 23 (29) 19 (21) 23 (20) 21 (28) 33 (29) 46 (25) 46 (36) 54 (34) 95 (46)
Nonindustry support (%) 19 (27) 27 (47) 24 (36) 37 (46) 52 (57) 82 (71) 26 (34) 50 (44) 61 (33) 55 (43) 42 (26) 41 (20)
Not stated (%) 6 (8) 0 (0) 7 (10) 8 (10) 8 (9) 3 (3) 6 (8) 1 (1) 32 (17) 0 (0) 13 (8) 4 (2)
Change in support (p-value)* — 0.047 — 0.041 — 0.101 — 0.255 — 0.251 — 0.498
*Comparison of number of trials with industry, mixed, and nonindustry support in 1996–1997 versus 2005–2006 using Mann-Whitney U-test (two-sided).
doi:10.1371/journal.pmed.1000354.t001
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sold. For ACP, the Internal Revenue Service data did not specify
the income, for AMA 53% of the income was from advertisements
and 12% from reprints (no data on supplements), and for MMS
23% of the income was from advertisements, whereas there were
no data on reprints and supplements.
Discussion
We found that the proportion of industry-supported trials varied
widely across journals but changed very little for each journal
within the studied time period. Industry-supported trials boosted
the approximate impact factor we calculated for all six journals—
the most for NEJM and the least for BMJ. Only the two European
journals disclosed their main sources of income, and the income
from selling reprints was hugely different, as it comprised 41% of
the total income for Lancet and only 3% for BMJ.
We believe this is the first study that investigates potential
conflicts of interest at medical journals in relation to citations and
financial income from publication of industry-supported trials.
Our data collection was systematic and thorough, but there are
also limitations. First, we selected major general medical journals
that publish many trials, and our findings may therefore not be
generalisable to other journals. Second, our assumption that trials
with no statement of support, or with nonindustry support, were
not industry supported may have led to an underestimation, as
undeclared industry involvement is common, e.g., in relation to
ghost authorship by medical writers’ agencies [9]. However, the
proportion of trials with no statement of support was very small in
the second period. Third, owing to the nature of the Web of
Science database, our identified citations were not the same as
those used when calculating journal impact factors in the Journal
Citation Reports. But as our aim was to study the relative
influence of industry-supported trials on the impact factor, this
discrepancy is likely not so important, as errors in citing studies
would be expected to be unrelated to the type of support they
received.
A problem related to the impact factor is that so-called
noncitable papers such as editorials, news pieces, and letters to
the editor contribute to the numerator, but not to the denominator
[10,11]. Because of this serious deficiency in the calculation, we
believe we have underestimated considerably the true influence of
industry-supported trials on the approximate impact factor. For
example, if we only include citations to citable papers (i.e., original
research and reviews) in an analysis of trials with industry and
mixed support, we find that the 2007 impact factor of NEJM
decreases by 24% instead of 15%.
There are several reasons why industry-supported trials are
generally more cited than other trials and other types of research.
They are often large and the most used interventions are drugs,
which are known to increase citations [12,13]. One explanation
might be that industry-supported trials are of higher quality than
Table 2. Citations for randomised trials published in major general medical journals and change in impact factors when industry-
supported trials are excluded.
Citation and Impact Factor Annals Archives BMJ JAMA Lancet NEJM
1996–
1997
2005–
2006
1996–
1997
2005–
2006
1996–
1997
2005–
2006
1996–
1997
2005–
2006
1996–
1997
2005–
2006
1996–
1997
2005–
2006
Mean n citations
a
Industry support 13.3 27.7 6.5 14.4 7.6 9.9 21.3 35.7 30.4 53.5 58.1 82.2
Mixed support 18.7 17.1 9.4 11.8 7.3 11.3 20.1 31.6 31.5 31.3 46.9 66.7
Nonindustry support 9.3 12.0 5.5 6.5 7.3 5.7 13.8 21.1 14.0 25.7 34.5 47.3
Not stated 10.8 — 10.9 8.3 8.0 5.0 5.7 32.0 10.0 — 33.4 30.3
Difference in citations
(p-value)
b
0.186 %0.001 0.237 %0.001 0.949 0.033 0.115 0.011 0.003 0.016 0.003 %0.001
Change in impact factor
Without trials with industry
support (%)
210 21 220023 23 25 24 27 27
Without trials with industry
and mixed support (%)
26 24 23 24 21 21 25 25 211 26 213 215
aFor each journal citations are reported for their impact factor year (i.e., citations in 1998 to trials published in 1996–1997 and in 2007 to trials published in 2005–2006).
bDifference in citations depending on type of support using Jonckheere-Terpstra test for trend (two-sided, support not stated excluded from the analysis).
doi:10.1371/journal.pmed.1000354.t002
Table 3. Relative income of journals and medical societies from sales of advertisements, reprints, and supplements and number of
reprints sold in 2005–2006.
Income and n Reprints Sold BMJ Lancet ACP (Annals) AMA (Archives and JAMA) MMS (NEJM)
Advertising (%) 16 1 Not stated 53 23
Reprints (%) 3 41 Not stated 12 Not stated
Supplements (%) 0 0 Not stated Not stated Not stated
n reprints sold 967,930 11,514,137 Not stated Not stated Not stated
doi:10.1371/journal.pmed.1000354.t003
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support this [14]. Interestingly, industry trials more often have
positive results than nonindustry trials [14], the conclusions in
negative trials are often presented in such a way that they appear
to be more positive than they actually are [15], and positive
industry trials are more cited than negative ones [12,13].
Furthermore, sponsoring companies may employ various strate-
gies to increase the awareness of their studies, including ghost
authored reviews that cite them [16–19], purchase and dissemi-
nation of reprints [20], and creation of media attention [12,21,22].
Such strategies are likely to be predominantly used for trials
favourable to the sponsors’ products, and this may put editors
under pressure, as they know which papers are especially attractive
for the companies [3].
Editors have an interest in increasing the impact factor for their
journal [23], whereas journal finances are generally regarded to be
in the hands of the publisher. However, editors also have an
interest in this, as they might be forced to fire staff if the journal
does not remain profitable, or at least viable. The former editor of
the BMJ, Richard Smith, reported that a single trial may lead to
an income of US$1 million for a journal from reprint sales [21],
and with a large profit margin of around 70% [3]. Journal
publishers therefore have an incentive to advertise the benefits of
reprints. As examples, the BMJ Group states that ‘‘Medical
specialists determine the success of your product or service. They
influence teaching, practice and purchase decisions within their
workplace and the whole specialty. Reach them through the BMJ
Group reprints service’’ [24], and NEJM states that ‘‘Article
reprints from the New England influence treatment decisions’’
[25]. The editor of The Lancet, Richard Horton, has described how
companies sometimes offer journals to purchase a large number of
reprints and may threaten to pull a paper if the peer review is too
critical [26]. For Lancet, a little less than half of the journal income
came from reprints, and though this applied to only 12% of AMA’s
income, it could be more for its most prestigious journal, JAMA.
Large incomes from reprint sales would also be expected for
NEJM, as it publishes more industry-supported trials than the
other journals.
This area warrants further research. Speciality journals could
also be investigated, particularly as conflicts of interest there could
be more pronounced as editors are often investigators themselves
and the degree of industry support may vary across specialities.
Influence from other types of industry-sponsored papers could also
be investigated. It would also be interesting to examine whether
income from advertisements can affect editorial decisions; for
example, one could compare the number of advertisements from
specific companies with the number of publications from the same
companies in a sample of journals. Such income can be substantial
for some journals [27]. When Annals published a study that was
critical of industry advertisements [28], it resulted in the loss of an
estimated US$1–1.5 million in advertising revenue [29]. Another
source of income that should be investigated is sponsored
subscriptions whereby companies pay for subscriptions for
clinicians, sometimes with a cover wrap displaying a company
product [30].
Although publication of industry-supported trials is favourable
for medical journals we cannot tell from our results whether
industry-supported trials have affected editorial decisions. The
high number of industry-supported trials in NEJM could merely
result from the fact that it has the highest impact factor and
therefore also receives more trial reports than other journals.
Nevertheless, disclosure of conflicts of interest is not about whether
relationships have actually influenced decisions, but whether they
potentially could have [1]. The International Committee of
Medical Journal Editors requires authors to ‘‘disclose interactions
with ANY entity that could be considered broadly relevant to the
work’’ [31]. We suggest that journals abide by the same standards
related to conflicts of interest, which they rightly require from their
authors, and that the sources and the amount of income are
disclosed to improve transparency.
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Background. Medical journals publish many different types
of papers that inform doctors about the latest research
advances and the latest treatments for their patients. They
publish articles that describe laboratory-based research into
the causes of diseases and the identification of potential new
drugs. They publish the results of early clinical trials in which
a few patients are given a potential new drug to check its
safety. Finally and most importantly, they publish the results
of randomized controlled trials (RCTs). RCTs are studies in
which large numbers of patients are randomly allocated to
different treatments without the patient or the clinician
knowing the allocation and the efficacy of the various
treatments compared. RCTs are best way of determining
whether a new drug is effective and have to be completed
before a drug can be marketed. Because RCTs are very
expensive, they are often supported by drug companies.
That is, drug companies provide grants or drugs for the trial
or assist with data analysis and/or article preparation.
Why Was This Study Done? Whenever a medical journal
publishes an article, the article’s authors have to declare any
conflicts of interest such as financial gain from the paper’s
publication. Conflict of interest statements help readers
assess papers—an author who owns the patent for a drug,
for example, might put an unduly positive spin on his/her
results. The experts who review papers for journals before
publication provide similar conflict of interest statements.
But what about the journal editors who ultimately decide
which papers get published? The International Committee of
Medical Journal Editors (ICMJE), which produces medical
publishing guidelines, states that: ‘‘Editors who make final
decisions about manuscripts must have no personal,
professional, or financial involvement in any of the issues
that they might judge.’’ However, the publication of
industry-supported RCTs might create ‘‘indirect’’ conflicts of
interest for journals by boosting the journal’s impact factor (a
measure of a journal’s importance based on how often its
articles are cited) and its income through the sale of reprints
to drug companies. In this study, the researchers investigate
whether the publication of industry-supported RCTs
influences the impact factors and finances of six major
medical journals.
What Did the Researchers Do and Find? The researchers
determined which RCTs published in the New England
Journal of Medicine (NEJM), the British Medical Journal
(BMJ), The Lancet, and three other major medical journals
in 1996–1997 and 2005–2006 were supported wholly, partly,
or not at all by industry. They then used the online academic
citation index Web of Science to calculate an approximate
impact factor for each journal for 1998 and 2007 and
calculated the effect of the published RCTs on the impact
factor. The proportion of RCTs with sole industry support
varied between journals. Thus, 32% of the RCTs published in
the NEJM during both two-year periods had industry support
whereas only 7% of the RCTs published in the BMJ in 2005–
2006 had industry support. Industry-supported trials were
more frequently cited than RCTs with other types of support
and omitting industry-supported RCTs from impact factor
calculations decreased all the approximate journal impact
factors. For example, omitting all RCTs with industry or
mixed support decreased the 2007 BMJ and NEJM impact
factors by 1% and 15%, respectively. Finally, the researchers
asked each journal’s editor about their journal’s income from
industry sources. For the BMJ and The Lancet, the only
journals that provided this information, income from reprint
sales was 3% and 41%, respectively, of total income in 2005–
2006.
What Do These Findings Mean? These findings show
that the publication of industry-supported RCTs was
associated with an increase in the approximate impact
factors of these six major medical journals. Because these
journals publish numerous RCTs, this result may not be
generalizable to other journals. These findings also indicate
that income from reprint sales can be a substantial
proportion of a journal’s total income. Importantly, these
findings do not imply that the decisions of editors are
affected by the possibility that the publication of an
industry-supported trial might improve their journal’s
impact factor or income. Nevertheless, the researchers
suggest, journals should live up to the same principles
related to conflicts of interest as those that they require from
their authors and should routinely disclose information on
the source and amount of income that they receive.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000354.
N This study is further discussed in a PLoS Medicine
Perspective by Harvey Marcovitch
N The International Committee of Medical Journal Editors
provides information about the publication of medical
research, including conflicts of interest
N The World Association of Medical Editors also provides
information on conflicts of interest in medical journals
N Information about impact factors is provided by Thomson
Reuters, a provider of intelligent information for businesses
and professionals; Thomson Reuters also runs Web of
Science
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